Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2783-2788

  Mose, Stephan ^a   Menzel, Christian ^a   Kurth, Andreas A ^a   Obert, Kirstin ^a   Breidert, Iris ^a   Borowsky, Karen ^a   Böttcher, Heinz Dietrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bisphosponates; Bone resorption marker; Endocrine therapy; Osseous metastases; Radiotherapy; Tartrate resistant acid phosphatase 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; HYDROXYPROLINE; OSTEOCALCIN; PEPTIDE; PROCOLLAGEN; PYRIDINOLINE; SIALOPROTEIN;

BONE METABOLISM; BONE METASTASIS; BREAST CARCINOMA; CANCER PATIENT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; HUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; REVIEW;

ACID PHOSPHATASE; BONE NEOPLASMS; HUMANS; ISOENZYMES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0043125544     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL and Watts NB: Practical clinical application of biochemical markers of bone turnover. J Clin Densitometry 2: 323-342, 1999.
2. Seibel MJ and Woitge HW: Biochemical markers of bone metabolism-Update 1999. Clin Lab 45: 237-256, 1999.
3. Woitge HW and Seibel MJ: Risk assessment for osteoporosis II. Biochemical markers of bone turnover: Bone resorption indices. Osteoporosis and Metabolic Bone Disease 20: 503-525, 2000.
4. Schmolke B: Labordiagnostik der Osteoporose. Orthopäde 30: 425-436, 2001.
5. Seregni E, Martinetti A, Ferrari L and Bombardieri E: Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors. Q J Nucl Med 45: 7-17, 2001.
6. Rosenbrock H, Seifert-Klauss V, Kaspar S, Busch R and Luppa PB: Changes of biochemical bone markers during menopausal transition. Clin Chem Lab Med 40:143-151, 2002.
7. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ and Väänänen HK: Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 15: 1337-1345, 2000.
8. Nakanishi M, Yoh K, Miura T, Ohasi T, Rai SK and Uchida K: Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem 46: 469-473, 2000.
9. Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J and Väänänen HK: Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into culture medium. Clin Chem 46: 1751-1754, 2000.
10. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel M and Väänänen HK: Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597-600, 2001.
11. Janckila AJ, Takahashi K, Sun SZ and Yam LT: Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47: 74-80, 2001.
12. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S and Väänänen HK: Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71: 20-25, 2002.
13. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T and Yam LT: Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clinca Chimica Acta 320: 49-58, 2002.
14. Igarashi Y, Lee MY and Matsuzaki S: Acid phosphatases as markers of bone metabolism. J Chromatography B 781: 345-358, 2002.
15. Lam KW, Eastlund DT, Li CY and Yam LT: Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 24: 1105-1108, 1978.
16. Yaziji H, Janckila AJ, Lear SC, Martin AW and Yam LT: Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoetic tissues. Am J Clin Path 104: 397-402, 1995.
17. Halleen JM and Ranta R: Tartrate-resistant acid phosphatase as a serum marker of bone resorption. Am Clin Lab 20: 29-30, 2001.
18. Scarnecchia L, Minisola S, Pacitti MT, Carnevale V, Romagnoli E, Rosso R and Mazzuoli GF: Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 51: 517-524, 1991.
19. Halleen JM, Hentunen TA, Hellman J and Väänänen HK: Human bone tartrate-resistant acid phosphatase: Purification and development of an immunoassay. J Bone Miner Res 11: 1444-1452, 1996.
20. Plebani M, Bernardi D, Zaninotto M, De Paoli M, Secchiero S and Sciacovelli L: New and traditional serum markers of bone metabolism in the detection of skeletal metatases. Clin Biochem 29: 67-72, 1996.
21. Wada N, Ishii S, Ikeda T, Enomoto K and Kitajima M: Serum tartrate-resistant acid phosphatase as a potential marker of bone metastases from breast cancer. Anticancer Res 19: 4515-4522, 1999.
22. Halleen JM, Hentunen TA, Karp M, Käkönen SM, Petterson K and Väänänen HK: Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 13: 683-687, 1998.
23. Halleen JM, Karp M, Viloma S, Laakson P, Hellman J, Käkönen SM, Stehan JJ, Holmes SD, Väänänen HK and Petterson K: Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies. J Bone Miner Res 14: 464-469, 1998.
24. Halleen JM, Alatalo SL, Suominen H, Janckila AJ and Väänänen HK: A novel immunoassay for serum tartrate-resistant acid-phosphatase 5b. Calcif Tissue Int 66 (Suppl. 1): 85, 2000.
25. Hannon RA, Eagleton AC, Clows JA, Machado ABC, Eastell R and Blumsohn A: Clinical evaluation of a novel activity-based immunoassay for tartrate resistant acid phosphatase (TRACP) isoform 5b. Osteopor Int 13 (Suppl. 1): 55, 2002.
26. Tsolkas H, Timmermann K, Holst G, Altrogge H and Müller-Wiefel DE: Tartrate-resistant acid phosphatase (TRAP) in children with chronic renal failure (CRF). Pediatric Nephrology 16: 458, 2001.
27. Wahl HG, Bandorski M, Bandorski D, Graf St, Sahlfeld D, Bohner J and Fassbinder W: Tartrate-resistant acid phosphatase isoform 5b (TRAP): a novel serum marker of bone resorption in haemodialysis patients. Congress of the European Renal Association, 6/2002.
28. Capeller B, Chaffier H, Sütterlin M and Dietl J: Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of osseous metastases in breast cancer patients. Anticancer Res 11 (1B): 480-481, 2002.
29. Lein M, Jung K, Stephan C, Schnorr D and Loening SA: Osteoprotegrin (OPG) and isoform 5b of tartrate-resistant acid phosphatase (TRAP) in serum as new marker of bone metastases in prostate cancer. Anticancer Res 22(1B): 510, 2002.
30. Mose St, Obert K, Breidert I, Borowsky K, Rahn A, Mitrou PS., Menzel C, Grünwald F and Böttcher HD: Tartrate-resistant acid phosphatase (TRAP) as specific serum marker of bone resorption in radiation therapy (RT) of bone metastases. Annals of Oncology 13 (Suppl. 5): 179-180, 2002.